Clinical effects and safety of piperacillin/tazobactam in treating neutropenic febrile patients with malignant hematopathy

Kai-yan LIU,Jin-song JIA,Juan LI,Chun WANG,De-pei WU,Liang-ding HU,Xiao-jun HUANG

DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2009.01.011

2009-01-01

Abstract:Objective To evaluate the effect and safety of piperacillin/tazobactam on neutropenic febrile patients with Malignant Hematopathy. Methods 218 patients with malignant hematopathy complicated by infectious fever, 162 (74.31%) with fever of unknown origin (FUO), 33 (15.14%) with clinically defined infection (CDI), and 23 (10.55%) with mierobiologically defined infection (MDI), underwent intravenous drip of piperacillin/tazobactam at the dose of 4.5 g for 30 min every 8 hours till 4 ～ 5 d after the temperature returned to normal or neutropenia was relieved. Twenty hours before and after treatment blood routine, blood biochemical and electrolytes, and bacteriological examination, chest X-ray examination were conducted. The changes of symptoms and signs were observed. Results The total effective rate was 65.60%, the bacteria clearance rate was 71.43%, and the adverse reaction rate was 5.04%. The average defervescence time was (2.5±1.2) days, and the duration of antibiotic therapy was (9.4±8.1) days. There were not significant differences in the curative effect and defervescence time between the patients undergoing chemotherapy and those undergoing hematopoietic stem cell transplantation (X2 =2.058,P >0.05, and t = 1.892,P >0.05). After the piperacillin/tazobactam treatment the white blood cell count and absolute neutrophile granulocyte count of the patients significantly increased(t =4.092, P <0.01 ;t = 4.248, P < 0.01). However, the hepatic and renal functions did not change obviously after tratmemt. Conclusions Piperaeillin/tazobaetam therapy is effective and safe empirical antibacterial therapy in febrile neutropenie patients with hematological malignancies.